Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Health Network, Toronto
About this trial
Donor organs often carry latent Cytomegalovirus (CMV) infection that may be transmitted to the recipient. The goal of this clinical trial is to determine the safety of SYN002 treatment during Ex-Vivo Organ Perfusion (EVOP) in clinical kidney transplantation. Donor kidneys will be treated on the EVOP system with SYN002 in order to decrease the burden of latent CMV in the organ and mitigate the transmission of cytomegalovirus (CMV).
Eligibility criteria
Qualifiers
Age ≥18 years
Listed for kidney transplantation
Either CMV seronegative or seropositive
Willing to provide written informed consent to take part in the trial
Disqualifiers
Listed for combined organ transplant (e.g. kidney-pancreas or kidney-liver)
Re-transplantation
HIV positive
Highly sensitized recipient with a PRA >=95
Trial design
Treatments tested in this trial
- SYN002
Treatment groups
12 Participants
are divided into 1 treatment groupLocations
1University Health Network, Toronto General Hospital, Ajmera Transplant CentreM5G 2N2, TorontoOntario, Canada
Sponsors and collaborators
University Health Network, Toronto
Lead sponsor
Source ClinicalTrials.gov